Goldman Sachs analyst Salveen Richter downgraded ... In the meantime, it takes a conservative view given competitive and commercial dynamics for nexiguran ziclumeran in transthyretin amyloidosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback